Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: A systematic review and meta-analysis

Mudhune, Godfrey H.; Armour, Mike; McBride, Kate A

doi:10.1016/j.breast.2019.06.002

Cited by 12 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51 A recent meta-analysis appraised the current evidence to date on HRT in breast cancer survivors, who were older, and concluded that caution with HRT use in breast cancer survivors is advisable. 52 However, it is important to note that individual studies show conflicting results and some…”

Section: Hrt Management In Specialized Populationsmentioning

confidence: 99%

“…Over two‐thirds of breast cancers are hormonally mediated and require up to a decade of endocrine therapies such as tamoxifen (TAM) or ovarian suppression/aromatase inhibitors and or oophorectomy 51 . A recent meta‐analysis appraised the current evidence to date on HRT in breast cancer survivors, who were older, and concluded that caution with HRT use in breast cancer survivors is advisable 52 . However, it is important to note that individual studies show conflicting results and some observational studies show no evidence of increased cancer recurrence with HRT use in this population 53,54 .…”

Section: Hormone Replacement Therapymentioning

confidence: 99%

See 1 more Smart Citation

Female reproductive health in pediatric, adolescent, and young adult cancer survivors

Hoefgen

Benoît

Chan

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

An estimated 500,000 cancer survivors of reproductive age in the United States will live to experience the long‐term consequences of cancer treatment. Therefore, a focused aspect of cancer care has appropriately shifted to include quality of life in survivorship. Infertility is a late effect of therapy that affects 12% of female survivors of childhood cancer receiving any cancer treatment in large cohort studies and results in a 40% decreased likelihood of pregnancy in young adults of ages 18–39 years. Nonfertility gynecologic late effects such as hypoestrogenism, radiation‐induced uterine and vaginal injury, genital graft‐versus‐host disease after hematopoietic stem cell transplant, and sexual dysfunction also significantly affect quality of life in survivorship but are underdiagnosed and require consideration. Several articles in the special edition “Reproductive Health in Adolescent and Young Adult Cancer Survivorship” address infertility, genital graft‐versus‐host disease, and psychosexual functioning in survivorship. This review article focuses on other adverse gynecologic outcomes of cancer therapies including hypogonadism and hormone replacement therapy, radiation‐induced uterovaginal injury, vaccination and contraception, breast and cervical cancer screening, and pregnancy considerations in survivorship.

show abstract

Section: Hrt Management In Specialized Populationsmentioning

confidence: 99%

Section: Hormone Replacement Therapymentioning

confidence: 99%

Female reproductive health in pediatric, adolescent, and young adult cancer survivors

Hoefgen

Benoît

Chan

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…A meta-analysis by Mudhune et al investigated whether the safety of HRT in women with (a history of) breast cancer differs according to their age at diagnosis (younger/older than 50 years). They concluded that there is sufficient evidence to suggest that HRT increases the risk of recurrence in women older than 50 years, but that this is unlikely to affect mortality ( Mudhune et al, 2019 ).…”

Section: Evidencementioning

confidence: 99%

Clinical guidelines for managing menopausal symptoms in women with (a history of) breast cancer

Servayge,

Verduyn,

Page

et al. 2023

Facts Views Vis ObGyn

View full text Add to dashboard Cite

Background: One in eight women will be diagnosed with breast cancer. At the time of diagnosis, 75% of patients are postmenopausal. Many will receive anti-hormone therapy, which often induces menopausal symptoms. Premenopausal breast cancer patients frequently become postmenopausal as a result of the treatment and often experience menopausal symptoms. The increased incidence of breast cancer, combined with longer survival, has led to an increase in the number of women experiencing menopausal symptoms. Therefore, the management of menopausal symptoms in women with a history or current breast cancer is a relevant and common clinical problem. Objectives: To provide a clinically useful overview of the steps in the management of menopausal symptoms in women with (a history of) breast cancer. Materials and methods: A comprehensive literature review was conducted by authors JS and WT using the PubMed and Medline databases. Abstracts were critically appraised and, where appropriate, the full text was analysed. Main outcome measures: Not applicable. Results: Depending on the condition, either meta-analyses, randomised controlled trials or retrospective cohorts were identified. No evidence was found for some proposed treatments. Conclusions: Menopausal symptoms in women with (a history of) breast cancer require a patient-tailored approach. Shared decision making is paramount and adequate up-to-date knowledge can help the breast cancer specialist to advise and guide patients accordingly. What is new? A comprehensive, clinically-based overview of evidence-based treatment options for menopausal symptoms in women with (a history of) breast cancer.

show abstract

“…The presence of a woman's metabolic syndrome (MS) exacerbates metabolic and endocrine disorders and subjective symptoms of menopause [17,18]. The dominant role of menopausal hormone therapy (MGT) in the treatment of pathological menopause has been established [19,20], but its metabolic and oncological safety remains debatable [21][22][23]. If there are contraindications to MGT or a woman refuses it, it is a serious problem to provide effective medical care without the use of estrogen-gestagenic drugs, both from the position of relieving subjective menopausal symptoms, and from the position of preventing cardiovascular complication.…”

Section: Introductionmentioning

confidence: 99%

The role of non-drug strategies in reducing the risk of cardiovascular complications in women with metabolic syndrome during the menopausal transition

Rr¹,

Ia²,

Sa³

2020

Clin Diagn Pathol

View full text Add to dashboard Cite

show abstract

Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: A systematic review and meta-analysis

Cited by 12 publications

References 38 publications

Female reproductive health in pediatric, adolescent, and young adult cancer survivors

Female reproductive health in pediatric, adolescent, and young adult cancer survivors

Clinical guidelines for managing menopausal symptoms in women with (a history of) breast cancer

The role of non-drug strategies in reducing the risk of cardiovascular complications in women with metabolic syndrome during the menopausal transition

Contact Info

Product

Resources

About